Abstract
Mesothelin is a cell surface glycoprotein that is overexpressed in various malignancies. Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-κB/PI3K/Akt signaling pathways. Herein, the expression of mesothelin in HER2-positive and triple-negative breast cancer (TNBC) has been correlated with prognosis. A total of 430 patients with breast cancer treated between 2006 and 2013 were retrospectively reviewed; of these, 123 cases were considered TNBC (n=71; 58%) or were positive for HER2 (n=52; 42%). Mesothelin expression was assessed by immunohistochemistry. Of the patients with TNBC, 30 (42.3%) were positive for mesothelin expression, compared to only two (3.8%) of the HER2-positive cases. As most HER2-positive tumors were negative for mesothelin staining, statistical analysis was not performed. Median overall survival (OS) was 70.1 months for patients with TNBC, whereas median OS was 70.1 months, in the mesothelin-positive group and 74.5 months in mesothelin-negative group, respectively. Strong correlation was seen between mesothelin expression and tumor grade in patients with TNBC (P<0.005). In a multivariable Cox proportional hazards model, mesothelin expres...Continue Reading
References
Mar 1, 1992·The American Journal of Surgical Pathology·K ChangM C Willingham
Feb 1, 1992·International Journal of Cancer. Journal International Du Cancer·K ChangM C Willingham
Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·K Chang, I Pastan
Mar 18, 2003·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Nelson G Ordóñez
Oct 25, 2003·The American Journal of Surgical Pathology·Nelson G Ordóñez
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raffit HassanIra Pastan
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Denise R ShawTheresa V Strong
Jan 19, 2006·American Journal of Clinical Pathology·Raffit HassanDaniel Brackett
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M Jim YenIe-Ming Shih
Nov 7, 2006·IUBMB Life·Zhimin Lu, Shuichan Xu
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mitchell HoIra Pastan
Apr 3, 2007·Gynecologic Oncology·Louis A DaintyG Larry Maxwell
Jun 15, 2007·Cancer·Wen-Fang ChengT-C Wu
Jun 22, 2007·Gene Therapy·C-L ChangC-F Hung
Oct 20, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Raffit Hassan, Mitchell Ho
Feb 19, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Oluf Dimitri RoeKristina Kjaerheim
Feb 19, 2008·Molecular Cancer Therapeutics·Min LiQizhi Yao
Nov 18, 2008·Molecular Cancer Research : MCR·Uddalak BharadwajQizhi Yao
Sep 15, 2009·The Biochemical Journal·Ming-Cheng ChangWen-Fang Cheng
Oct 6, 2010·Journal of Cancer·Liping YuMitchell Ho
Nov 3, 2010·Journal of Oncology Practice·M Elizabeth H HammondSarah Temin
Apr 26, 2011·Carcinogenesis·Uddalak BharadwajQizhi Yao
Jul 22, 2011·Pancreas·Takahiro EinamaSatoru Todo
Jul 23, 2011·Journal of Surgical Oncology·Kenji BabaShoji Natsugoe
Mar 16, 2012·Breast Cancer Research and Treatment·Julia TchouPaul J Zhang
Aug 22, 2012·The Journal of International Medical Research·L WangY Wang
Jul 3, 2013·Clinical Breast Cancer·Napa ParinyanitikulAna Maria Gonzalez-Angulo
Citations
Aug 16, 2016·Systematic Reviews·Mei WangLehana Thabane
Dec 25, 2017·Journal of Cell Communication and Signaling·Salma Abdi MahmoudJianwu Tang
Oct 1, 2020·Journal of Biochemical and Molecular Toxicology·Amoura M Abou-El-NagaRami M Elshazli
Jul 30, 2019·Frontiers in Immunology·Joanie Del BanoBrigitte Kerfelec
Oct 22, 2019·Biotechnology and Bioengineering·Allison R SiroisSarah J Moore
May 1, 2021·Biomedicines·Sören WeidemannRonald Simon